痛风 中国就医指南

Gout is a common, painful form of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and soft tissues, resulting from chronic hyperuricemia—serum uric acid levels exceeding 6.8 mg/dL. It predominantly affects the first metatarsophalangeal joint (podagra), but can involve ankles, knees, wrists, fingers, and elbows. Pathogenesis involves impaired renal urate excretion (accounting for ~90% of cases) or, less commonly, overproduction due to enzymatic defects (e.g., PRPS hyperactivity, HGPRT deficiency), dietary purine excess, or metabolic comorbidities. Urate crystal deposition triggers NLRP3 inflammasome activation, leading to IL-1β–driven neutrophil infiltration, synovial inflammation, and acute flares lasting 3–10 days untreated. Chronic gout may progress to tophaceous deposits, joint erosion, and irreversible damage if uncontrolled. Epidemiologically, gout affects approximately 1–4% of adults globally, with rising prevalence in China—estimated at 1.1–3.2% among adults aged ≥18 years—and higher incidence in men (peak onset 40–50 years) and postmenopausal women. Key modifiable risk factors include obesity (BMI ≥25 kg/m²), excessive alcohol intake (especially beer and spirits), high-purine diets (red meat, shellfish, organ meats), fructose-sweetened beverages, hypertension, chronic kidney disease (CKD stages 2–4), diuretic use (e.g., thiazides), and metabolic syndrome. Non-modifiable risks include male sex, aging, genetic predisposition (e.g., SLC2A9, ABCG2 variants), and family history. Gout significantly impairs quality of life: recurrent flares cause severe pain, functional limitation, work absenteeism, sleep disruption, anxiety, and depression. Patients often report reduced mobility, social withdrawal, and diminished participation in daily activities—even during intercritical periods. Untreated gout increases long-term cardiovascular risk (e.g., myocardial infarction, stroke) and accelerates CKD progression. Early diagnosis via clinical criteria (e.g., ACR/EULAR 2015 classification), serum uric acid testing, synovial fluid analysis (gold standard for crystal identification), and dual-energy CT (for tophus detection) is essential. Management requires a dual-phase strategy: rapid anti-inflammatory control of acute flares (NSAIDs, colchicine, or glucocorticoids), followed by long-term urate-lowering therapy (ULT) targeting serum uric acid <6.0 mg/dL (<5.0 mg/dL for tophaceous disease) using xanthine oxidase inhibitors (allopurinol, febuxostat) or uricosurics (lesinurad, benzbromarone where available). Lifestyle modification—including weight loss, low-purine diet, alcohol moderation, hydration, and avoidance of fasting or rapid weight loss—is foundational. Patient education on adherence, flare prophylaxis during ULT initiation, and comorbidity management is critical for sustainable outcomes.

# 痛风（内分泌科）治疗方案与费用明细

一、非手术/保守治疗方案

• •适用人群：急性期缓解后、血尿酸＞420 μmol/L、无痛风石或肾结石者
• •药物治疗（3个月疗程）：

- 急性期抗炎（秋水仙碱/NSAIDs）：50–300元/次发作

• •检查检验费：血尿酸、肝肾功能、尿常规、24h尿尿酸、超声关节扫描：480–950元/次

二、微创/介入治疗方案

• •适用人群：单发痛风石＞1.5cm、压迫神经或影响关节活动、药物难控者
• •关节镜下痛风石清除术（非根治性，属内分泌科联合骨科开展）：

- 手术+麻醉+住院（5–7天）：12,000–22,000元（含耗材、病理）

三、复杂/并发症/晚期方案

• •慢性痛风性肾病（CKD 3–4期）+多发痛风石：需个体化降尿酸+血液透析支持+多学科管理
• •全套年度综合管理（含SGLT2i保护肾功能、尿酸酶制剂培格洛酶）：8–15万元/年（培格洛酶单次注射约1.2万元，每2周1次）

四、方案快速选择指南

• •预算＜2000元/年：优选基础药物+生活方式干预（限酒、低嘌呤饮食）
• •中等预算（5000–30000元/年）：规范降尿酸+定期监测+超声随访
• •高需求/难治性患者：推荐多学科门诊+培格洛酶或关节镜微创干预